The EU Commission seemed to have confirmed a delay to the mandatory implementation of EUDAMED by posting a new draft timeline to its website.

The draft timeline indicates that all six of the modules will not be in a position to undergo independent audits before Q4 of 2026, this is primarily due to the Clinical Investigations and Performance Studies Module. Furthermore, the audit is expected to be successfully completed by Q2 of 2027. After the successful audit, use of EUDAMED will be published in the Official Journal of the EU.

As from Q2 of 2027:

  • There will be a 6-month transition period for the Actor, Vigilance, Market Surveillance, and Clinical Investigation and Performance Studies modules, becoming mandatory in Q4 of 2027, as per Article 123 (3) (d) MDR/113 (3) (f) IVDR.
  • There will be a 24-month transition period for the UDI/Device Registration and Notified Body and Certificates Modules, becoming mandatory in Q2 of 2029, as per article 123 (3) (e) MDR/113 (3) (a) IVDR.

The full timeline published by the EU Commission can be accessed using the following link Are you ready for the mandatory implementation of EUDAMED? Visit Medilink member Advena’s website to learn more about how they can help you prepare for the upcoming changes.

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…